Article provided by: Cherie C Binns RN MSCN
As
SARS-CoV-2, the virus that causes COVID-19, continues to evolve, monoclonal antibodies are no
longer effective against newer Omicron subvariants.
The monoclonal antibody treatment bebtelovimab is no
longer effective against BQ.1 and BQ.1.1.
As of November 30, FDA no longer
authorizes bebtelovimab for emergency use because of circulating variants.
Additionally, clinicians and patients should be aware of decreased
effectiveness against the pre-exposure prophylaxis, tixagevimab and cilgavimab
(EVUSHELD™), due to the proportion of circulating variants.
However, other
antiviral treatments remain effective.
Similar article information found here
Click to Subscribe for the MS Beacon eNewsletter and MS educational events